These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea. Lozano-Ortega G, Goring S, Bennett HA, Bergenheim K, Sternhufvud C, Mukherjee J. Curr Med Res Opin; 2016 May; 32(5):807-16. PubMed ID: 26700585 [Abstract] [Full Text] [Related]
6. Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials. Lyu X, Zhu X, Zhao B, Du L, Chen D, Wang C, Liu G, Ran X. Sci Rep; 2017 Mar 21; 7():44865. PubMed ID: 28322294 [Abstract] [Full Text] [Related]
9. [Drug treatment of type 2 diabetes]. Tielmans A, Laloi-Michelin M, Coupaye M, Virally M, Meas T, Guillausseau PJ. Presse Med; 2007 Feb 21; 36(2 Pt 2):269-78. PubMed ID: 17258675 [Abstract] [Full Text] [Related]
10. Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative. Vashisht R, Jung K, Schuler A, Banda JM, Park RW, Jin S, Li L, Dudley JT, Johnson KW, Shervey MM, Xu H, Wu Y, Natrajan K, Hripcsak G, Jin P, Van Zandt M, Reckard A, Reich CG, Weaver J, Schuemie MJ, Ryan PB, Callahan A, Shah NH. JAMA Netw Open; 2018 Aug 03; 1(4):e181755. PubMed ID: 30646124 [Abstract] [Full Text] [Related]
11. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors. Kumar A. Diabetes Metab Res Rev; 2012 Dec 03; 28 Suppl 2():21-5. PubMed ID: 23280862 [Abstract] [Full Text] [Related]
13. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. McIntosh B, Cameron C, Singh SR, Yu C, Ahuja T, Welton NJ, Dahl M. Open Med; 2011 Dec 03; 5(1):e35-48. PubMed ID: 22046219 [Abstract] [Full Text] [Related]
14. Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. Monami M, Cremasco F, Lamanna C, Marchionni N, Mannucci E. Diabetes Metab Res Rev; 2011 May 03; 27(4):362-72. PubMed ID: 21309062 [Abstract] [Full Text] [Related]
15. Dipeptidyl peptidase-4 inhibitor sitagliptin improves pancreatic β-cell function in hypertensive diabetic patients treated with angiotensin receptor blockers. Fukui K, Kawahito H, Wakana N, Kikai M, Terada K, Yamamoto K, Irie D, Kato T, Miyagawa S, Yamada H. J Renin Angiotensin Aldosterone Syst; 2015 Dec 03; 16(4):1001-9. PubMed ID: 26195265 [Abstract] [Full Text] [Related]
16. The effect of a dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta-analysis. Dai X, Wang H, Jing Z, Fu P. Curr Med Res Opin; 2014 Sep 03; 30(9):1777-86. PubMed ID: 24805140 [Abstract] [Full Text] [Related]
17. Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis. Foroutan N, Muratov S, Levine M. Clin Invest Med; 2016 Apr 02; 39(2):E48-62. PubMed ID: 27040861 [Abstract] [Full Text] [Related]
18. The effects of incretin-based therapies on β-cell function and insulin resistance in type 2 diabetes: A systematic review and network meta-analysis combining 360 trials. Wu S, Gao L, Cipriani A, Huang Y, Yang Z, Yang J, Yu S, Zhang Y, Chai S, Zhang Z, Sun F, Zhan S. Diabetes Obes Metab; 2019 Apr 02; 21(4):975-983. PubMed ID: 30536884 [Abstract] [Full Text] [Related]
19. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors. Boland CL, Degeeter M, Nuzum DS, Tzefos M. Ann Pharmacother; 2013 Apr 02; 47(4):490-505. PubMed ID: 23548652 [Abstract] [Full Text] [Related]
20. In type 2 diabetes patients, insulin glargine is associated with lower postprandial release of intact proinsulin compared with sulfonylurea treatment. Pscherer S, Larbig M, von Stritsky B, Pfützner A, Forst T. J Diabetes Sci Technol; 2012 May 01; 6(3):634-40. PubMed ID: 22768894 [Abstract] [Full Text] [Related] Page: [Next] [New Search]